GRANULES

- Granules India Limited informed the exchange about a change in the corporate office address of its Registrar and Share Transfer Agent (RTA), KFin Technologies Limited. - The new corporate office address is effective from December 01, 2026, located in Kokapet, Hyderabad.

Current scenario - Q2 FY27 revenue grew 20% YoY to INR15,600 million, crossing INR15,000 million quarterly revenue for the first time. - EBITDA grew 21% YoY to INR3,376 million with an EBITDA margin of 21.6%; PAT increased 39% YoY to INR1,818 million. - Gagillapur facility underwent a U.S. FDA cGMP inspection resulting in 11 observations; remediation plans and responses are being prepared with no impact on current commercial operations. Changes in trends - Gross margins moderated by 134 bps YoY to 64.4% due to higher input and logistics costs driven by West Asia conflicts. - Company shifted to a net cash position of INR8,280 million following the receipt of balance proceeds of warrants. Management Guidance & Outlook - Management remains confident in the underlying growth momentum, targeting sustained revenue and absolute profit growth despite short-term margin pressures. - Peptide CDMO business under Senn Tides is expected to move toward EBITDA/PAT neutrality by the end of FY27, backed by strong RFP flows and upcoming execution in Q4. Capex & Growth Drivers - Planned INR2,000 crores organic capex over the next 3-4 years will support peptide CDMO expansion (Zurich and Vizag), U.S. platform manufacturing, oncology, and API capacities. - Focus on complex generics, first-to-file opportunities, and global geographic expansion to drive medium to long-term growth.

- Granules India Limited has submitted intimation regarding the audio recording of the Earnings Conference Call for Q2 and half-year of FY27. - The conference call was held following results announcement. - The audio recording link has been made available on the company's official website.

- Q2 FY27 Revenue rose 20% YoY to ₹1,560 Cr; PAT surged 39% YoY to ₹181.8 Cr. - EBITDA increased 21% YoY to ₹337.6 Cr with a 21.6% margin. - Company achieved net cash of ₹828 Cr, supporting planned ~₹2,000 Cr organic capex over 3–4 years.

Q2 FY27 Consolidated Revenue ₹15,600 Mn vs ₹12,970 Mn (▲20% YoY) EBITDA ₹3,376 Mn vs ₹2,782 Mn (▲21% YoY) PAT ₹1,818 Mn vs ₹1,306 Mn (▲39% YoY) EBITDA Margin 22% vs 21% (▲100bps)

Q2 FY27 Consolidated Revenue ₹1,560Cr vs ₹1,297Cr (▲20% YoY) EBITDA ₹338Cr vs ₹278Cr (▲21% YoY) PAT ₹182Cr vs ₹131Cr (▲39% YoY) EBITDA Margin 21.6% vs 21.5% (▲19bps)